195 related articles for article (PubMed ID: 35893310)
1. Olfaction Recovery following Dupilumab Is Independent of Nasal Polyp Reduction in CRSwNP.
Cantone E; De Corso E; Ricciardiello F; Di Nola C; Grimaldi G; Allocca V; Motta G
J Pers Med; 2022 Jul; 12(8):. PubMed ID: 35893310
[TBL] [Abstract][Full Text] [Related]
2. Measuring Nasal Patency and the Sense of Smell in CRSwNP Patients Treated with Dupilumab.
Ottaviano G; De Corso E; Cantone E; Ciofalo A; Saccardo T; Bernardi R; Mairani E; Montuori C; Roccuzzo G; Soldati L; Randon B; Zampollo S; Chicco AD; Visconti F; Scarpa B; Nicolai P
J Pers Med; 2023 Jan; 13(2):. PubMed ID: 36836468
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).
De Corso E; Pasquini E; Trimarchi M; La Mantia I; Pagella F; Ottaviano G; Garzaro M; Pipolo C; Torretta S; Seccia V; Cantone E; Ciofalo A; Lucidi D; Fadda GL; Pafundi PC; Settimi S; Montuori C; Anastasi F; Pagliuca G; Ghidini A; Cavaliere C; Maffei M; Bussu F; Gallo S; Canevari FRM; Paludetti G; Galli J;
Allergy; 2023 Oct; 78(10):2669-2683. PubMed ID: 37203259
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Dupilumab in the Treatment of Patients with Uncontrolled Severe CRSwNP: A "Real-Life" Observational Study in Naïve and Post-Surgical Patients.
Ottaviano G; Saccardo T; Roccuzzo G; Bernardi R; Chicco AD; Pendolino AL; Scarpa B; Mairani E; Nicolai P
J Pers Med; 2022 Sep; 12(9):. PubMed ID: 36143311
[TBL] [Abstract][Full Text] [Related]
5. Dupilumab (Dupixent
Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Dupilumab on Work Productivity and Emotional Health in CRSwNP: A Multicentric Study in Northeast Italy.
Ottaviano G; Roccuzzo G; Lora L; Bison E; Tosin E; Calvanese L; Cestaro W; Locatello LG; Corlianò F; Stellin M; Baldovin M; Trimarchi MV; Bertocco AG; Maculan M; Scarpa B; Saccardo T; Nicolai P
J Pers Med; 2024 Apr; 14(5):. PubMed ID: 38793051
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Bachert C; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Joish VN; Chao J; Mannent LP; Amin N; Abbe A; Taniou C; Fan C; Pirozzi G; Graham NMH; Mahajan P; Staudinger H; Khan A
Allergy; 2020 Jan; 75(1):148-157. PubMed ID: 31306495
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP.
Bachert C; Zinreich SJ; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Amin N; Joish VN; Fan C; Zhang D; Staudinger H; Pirozzi G; Graham NMH; Khan A; Mannent LP
Rhinology; 2020 Feb; 58(1):10-17. PubMed ID: 31671432
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and rapidity on olfatory fuction recovery in CRS patients treated with Dupilumab: a real life prospective controlled study.
La Mantia I; Grigaliute E; Ragusa M; Cocuzza S; Radulesco T; Saibene AM; Calvo-Henriquez C; Fakhry N; Michel J; Maniaci A
Eur Arch Otorhinolaryngol; 2024 Jan; 281(1):219-226. PubMed ID: 37594543
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of dupilumab in real-life settings: a STROBE study.
Gal A; Gravier-Dumonceau R; Penicaud M; Ebode D; Radulesco T; Michel J
Eur Arch Otorhinolaryngol; 2024 Mar; ():. PubMed ID: 38498194
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Dupilumab in the Treatment of Adult and Older Adult Patients with Severe, Uncontrolled CRSwNP.
Ottaviano G; De Corso E; Saccardo T; D'Auria LM; Zampollo S; D'Agostino G; Mairani E; De Maio G; Scarpa B; Bacci C; Favero V
J Pers Med; 2023 Aug; 13(8):. PubMed ID: 37623491
[TBL] [Abstract][Full Text] [Related]
13. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
Mullol J; Bachert C; Amin N; Desrosiers M; Hellings PW; Han JK; Jankowski R; Vodicka J; Gevaert P; Daizadeh N; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1086-1095.e5. PubMed ID: 34628065
[TBL] [Abstract][Full Text] [Related]
14. Indirect Treatment Comparison of Biologics in Chronic Rhinosinusitis with Nasal Polyps.
Peters AT; Han JK; Hellings P; Heffler E; Gevaert P; Bachert C; Xu Y; Chuang CC; Neupane B; Msihid J; Mannent LP; Guyot P; Kamat S
J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2461-2471.e5. PubMed ID: 33548517
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics.
Busse WW; Pavord ID; Siddiqui S; Khan AH; Praestgaard A; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2023; 16():411-419. PubMed ID: 37096015
[TBL] [Abstract][Full Text] [Related]
16. Real-life effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps. Results from eight Hungarian centres with 12-month follow-up.
Kiricsi A; Bella Z; Kraxner H; Szaloki T; Fent Z; Liktor B; Huszka J; Laszlo P; Gobol D; Helfferich F; Vaska Z; Piski Z; Juhasz-Loisch L; Horvath B; Galantai G; Krisztin N; Toth L; Bodi A; Matuz M; Lujber L; Hirschberg A
Rhinology; 2024 Jun; ():. PubMed ID: 38848046
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies.
Lee SE; Hopkins C; Mullol J; Msihid J; Guillemin I; Amin N; Mannent LP; Li Y; Siddiqui S; Chuang CC; Kamat S; Khan AH
Allergy; 2022 Jul; 77(7):2211-2221. PubMed ID: 35034364
[TBL] [Abstract][Full Text] [Related]
19. Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy.
Albrecht T; Sailer MM; Capitani F; van Schaik C; Löwenheim H; Becker S
World Allergy Organ J; 2023 May; 16(5):100780. PubMed ID: 37234094
[TBL] [Abstract][Full Text] [Related]
20. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis.
Napolitano M; Maffei M; Patruno C; Leone CA; Di Guida A; Potestio L; Scalvenzi M; Fabbrocini G
Dermatol Ther; 2021 Nov; 34(6):e15120. PubMed ID: 34472171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
